The acute pain drug market will increase to $17.4 billion through 2021 in the United Sates, France, Germany, Italy, Spain, the United Kingdom and Japan, finds Decision Resources, in Burlington, Mass., a research and advisory firm for pharmaceutical and healthcare issues.
According to the company, opioid analgesics and nonsteroidal anti-inflammatory drugs will continue to hold leading market status in the acute pain space while new analgesics that will launch over the next decade will not have a significant impact on major market sales or the treatment paradigm for acute pain. In 2011, sales of opioid analgesics and nonsteroidal anti-inflammatory drugs combined, made up more than half of the total major market sales, said Andrea Buurma, a Decision Resources analyst. This trend is expected to continue through 2021.
Sheikh Zayed Institute for Pediatric Surgical Innovation to Open Children's Pain Medicine Clinic
Interventional Pain Specialist Joins New England Spine Clinic
According to the company, opioid analgesics and nonsteroidal anti-inflammatory drugs will continue to hold leading market status in the acute pain space while new analgesics that will launch over the next decade will not have a significant impact on major market sales or the treatment paradigm for acute pain. In 2011, sales of opioid analgesics and nonsteroidal anti-inflammatory drugs combined, made up more than half of the total major market sales, said Andrea Buurma, a Decision Resources analyst. This trend is expected to continue through 2021.
More Articles on Pain Management:
Physician's Technology Introduces 5th Generation Device for Joint Pain ReliefSheikh Zayed Institute for Pediatric Surgical Innovation to Open Children's Pain Medicine Clinic
Interventional Pain Specialist Joins New England Spine Clinic